2 Cheap Stocks That Could Rise 100% This Summer

The coronavirus crash created a ton of buying opportunities. While the rebound erased many of those options, there are still dirt-cheap stocks worth buying that could rise more than 100% over the next few months. Of course, massive upside comes with some added risk. But the two picks below look outrageously priced given the potential upside in the second half…

Read More

2 Pot Stocks to Buy in June

Pot stocks had a wild ride last decade. We saw the near-instant formulation of billion-dollar markets. Several upstarts attained $1 billion valuations within weeks, despite having little to no operating history. Then, almost as suddenly, the market experienced a precipitous fall. Marijuana ETFs were cut in half last year. Many pot producers are now on the brink of bankruptcy. Yet…

Read More

Cannabis Investors: Expect a Bull Market in 2020

Cannabis investors have been on a roller coaster in recent years. In 2018, pot stocks were zooming. But last year, the bottom fell out, with most marijuana ETFs falling by more than 50%. Unfortunately, 2020 has brought more pain. The coronavirus pandemic and oil downturn have dragged the entire stock market lower. But here’s the thing: pot demand continues to…

Read More

Contraction Is the New Trend for Cannabis Stocks

A year ago, many investors in Canada’s cannabis industry were boasting of their incredible returns. Investors were doubling or tripling their money in a short amount of time on any company that planted a cannabis plant with a licence from Health Canada. Since a year ago, most of these same companies have been halved three times over. The broader Horizons…

Read More

If You’re Going to Buy Weed, Buy It in Aggregate

If you haven’t noticed, Canadian cannabis producers are risky to own. The same volatility that allowed these companies to double on a weekly basis has allowed some of the same names to halve a weekly basis. Here’s my take on why investors looking to invest in cannabis ought to buy the Exchange-Traded Fund (ETF) tracking the sector: the Horizons Marijuana…

Read More

Cannabis: Put That in Your Beverage and Drink it?

Boy, oh boy. Everyone saw this coming. I mean, valuations in the Canadian cannabis industry a year ago were just loony. Anyone who read my piece “Bigger Bubble: Cryptocurrencies or Cannabis” were warned of this near the peak. That’s ancient history now, but with the overall cannabis sector down over 70% from these highs, my hopes are that folks who…

Read More

How to Make Money From Massive Volatility in the Cannabis Sector in 2020

Talking about volatility in investing is often a one-sided conversation. In other words, most people expect a stock to go up or down, but typically in one direction. With the Canadian cannabis industry, any investor who has seen a stock chart of the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) will know that volatility on both ends of the spectrum has…

Read More

3 Warning Signs for Cannabis Investors

Boy, what a year 2019 was for investors in Canada’s new cannabis industry. The mood among many has certainly shifted, and the euphoria with which companies were gobbling each other up has abated. Horizons Marijuana Life Sciences Index ETF is now down 65% from its 52-week high in early 2019 (not its overall peak). Questions about where the bottom is remain, and…

Read More

Why Canopy Growth (TSX:WEED) Stock Can Get Back All-Time Highs in 2020

The second phase of cannabis legalization in Canada, often called “Cannabis 2.0,” has reinvigorated many stocks in the sector over the last few months. Cannabis ETFs have gained momentum after being pummeled for most of 2019. Horizons Marijuana Life Sciences ETF has increased 7.6% over the past month as of close on January 16. Canopy Growth remains the biggest Canadian cannabis player. Shares…

Read More

This $520-Million Pot Stock Is Now Too Cheap to Ignore

Demand for legal pot continues to climb to new heights. Investment bank Cowen Inc has raised its 2030 sales forecast from $75 billion to $80 billion, only to bump it again to $85 billion last November. Globally, several analysts are now expecting sales to peak above $200 billion. If adjacent markets are any indication, even these rosy estimates could prove…

Read More